Bogliolo, M.,
Catucci, I.,
Caleca, L.,
Lasheras, S.V.,
Pujol, R.,
Kiiski, J.I.,
Muranen, T.A.,
Barnes, D.R.,
Dennis, J.,
Michailidou, K.,
Bolla, M.K.,
Leslie, G.,
Figlioli, G. (2019) variants in DNA repair genes BRCA1, BRCA
2, PALB
2, ATM, and CHEK
2 are associated with breast cancer risk
Beylerli, Ozal,
Gareev, Ilgiz,
Musaev, Elmar,
Roumiantsev, Sergey,
Chekhonin, Vladimir,
Ahmad, Aamir,
Chao, Yuan,
Yang, Guang (2025) tumors, including receptor tyrosine
kinase (RTK) inhibitors, PI3K/AKT/mTOR inhibitors, RAF
Asadullina, D.D.,
Gilyazova, I.R.,
Ivanova, E.A.,
Izmailova, S.M.,
Gilyazova, G.R.,
Pavlov, V.N.,
Khusnutdinova, E.K. (2024) prognosis and difficult to treat. Despite significant advances in the treatment of ccRCC, immune
checkpointIvanova, Elizaveta,
Asadullina, Dilara,
Gilyazova, Gulshat,
Rakhimov, Radmir,
Izmailov, Adel,
Pavlov, Valentin,
Khusnutdinova, Elza,
Gilyazova, Irina (2023) Immunotherapy with immune
checkpoint inhibitors (ICIs) has shown high efficiency in
clear cell